Compare Hims and Hers Health Inc (HIMS) vs Vistra Corp (VST) Price & Performance

Hims & Hers Health trades at $32.70, down 0.43% on the day, with a bearish technical signal despite bullish moving averages. The company reported $2.35 billion in 2025 revenue but swung to a projected net loss for 2026, with mixed quarterly earnings results. Recent news highlights executive changes and anticipation for Q2 2026 results on August 10, 2026, with analyst sentiment leaning toward a Buy consensus.

The outlook is cautious due to profitability concerns and high valuation multiples, but growth opportunities in weight-loss and telehealth services offer potential. Key risks include execution challenges and regulatory scrutiny. The stock presents a speculative growth play with a consensus price target of $33.57, slightly above the current price.

Vistra Corp (VST) trades at $157.99, up 1.64% today, showing mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, the company reported strong Q1 2026 earnings beat ($2.87 vs $1.32 expected) after previous misses, with 2026 revenue projected at $19.4B and net profit margin improving to 11.52%. Recent news highlights Vistra's positioning as a potential beneficiary of AI-driven power demand growth.

Wall Street maintains strong bullish sentiment with 91% buy ratings and a $253 consensus price target representing 60% upside potential. Key risks include power price volatility, high debt levels, and project execution challenges. The company's long-term power purchase agreements with major tech firms provide revenue visibility, but investors should monitor Q2 2026 earnings due August 7th for confirmation of growth trajectory.